JPRN-UMIN000031205已完成未知
A prospective study evaluating efficacy of ALA HCl for diagnosis of upper urinary tract urothelial carcinoma - efficacy of ALA HCl for diagnosis of upper urinary tract urothelial carcinoma
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences0 个研究点目标入组 20 人开始时间: 2018年3月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
Based on the results for these 18 patients, the sensitivity and specificity of ALA-PDD were calculated to be 80.0% and 33.3%, respectively, whereas for white light observation the respective values were 86.7% and 66.7% (Table 2). The PPV and NPV of ALA-PDD were 59.5% and 70.0%, respectively. The combined observation had the highest sensitivity at 72.5%, but the lowest specificity at 51.9%.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with allergy to ALA HCl or porphyrin, light hypersensitivity Patients with administration of the drugs which are contraindicated contraindication with ALA HCl Pregnant or lactating woman Patients with severe underlying diseases such as cardiovascular event, liver disfunction, diabetes mellitus, and so on. Patients who have been enrolled into another study.
研究者
相似试验
已完成
3 期
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaChronic Idiopathic UrticariaNCT05774639Kashiv BioSciences, LLC600
已完成
2 期
Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid ArthritisArthritis, RheumatoidNCT00867516CSL Behring127
已完成
不适用
Comparison of ProSeal Laryngeal Mask Airway, LTS-D and I-gel in Mechanically Ventilated PatientsAirway MorbidityNCT02877940Government Medical College, Haldwani150
已完成
不适用
Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)AnthraxNCT04320485InBios International, Inc.450
招募中
3 期
A Study to Evaluate the Efficacy and Safety of AD-218Mixed DyslipidemiaNCT05400317Addpharma Inc.520